Staphylococcus aureus Bacteremia, Risk Factors, Complications, and Management - 05/07/13
Doi : 10.1016/j.ccc.2013.03.008
Yoav Keynan, MD, Ethan Rubinstein, MD, LLB ⁎ 
Section of Infectious Diseases, Department of Internal Medicine and Medical Microbiology, University of Manitoba, 543-745 Bannatyne Ave, Basic Sciences Bldg, Manitoba R3E 0J9, Canada
∗Corresponding author.
Résumé |
Staphylococcus aureus and methicillin-resistant S aureus have emerged as the most important nosocomial pathogens. Traditional therapy may be sufficient in most but not all patients, in whom alternatives should be sought. The infection is often complicated with several sites of metastatic foci and is nosocomial frequently. New antibiotics to fight MRSA have been introduced and are equivalent or better than vancomycin.
Le texte complet de cet article est disponible en PDF.Keywords : Staphylococcus aureus, Infection, MSSA, MRSA, Treatment, Antibiotics, Vancomycin, Linezolid, VAP, HAP
Plan
© 2013
Elsevier Inc. Tous droits réservés.
Vol 29 - N° 3
P. 547-562 - juillet 2013 Retour au numéro
Article précédent
- Nosocomial Pneumonia : Lessons Learned
- Girish B. Nair, Michael S. Niederman
- Severe Community-Acquired Pneumonia
- Wendy I. Sligl, Thomas J. Marrie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?